Stockscreener 앱 받기
10.29
3.21%
0.32
전일 마감가:
$9.97
열려 있는:
$9.96
하루 거래량:
302.91K
Relative Volume:
0.93
시가총액:
$531.17M
수익:
$227.18M
순이익/손실:
$24.38M
주가수익비율:
21.55
EPS:
0.4774
순현금흐름:
$53.60M
1주 성능:
+8.20%
1개월 성능:
+13.70%
6개월 성능:
+31.92%
1년 성능:
+97.50%
1일 변동 폭
$9.85
$10.36
1주일 범위
$9.33
$10.36
52주 변동 폭
$4.575
$10.36
Puma Biotechnology Inc Stock (PBYI) Company Profile
명칭
Puma Biotechnology Inc
전화
(424) 248-6500
주소
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
10.29 | 504.33M | 227.18M | 24.38M | 53.60M | 0.4774 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-28 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Underperform |
| 2019-10-08 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-10 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-01-17 | 개시 | Leerink Partners | Mkt Perform |
| 2019-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-11-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-11-02 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-17 | 개시 | Goldman | Sell |
| 2018-05-11 | 재확인 | Stifel | Buy |
| 2017-11-10 | 재확인 | Citigroup | Buy |
| 2017-11-10 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | 재확인 | Stifel | Buy |
| 2017-09-11 | 재확인 | Credit Suisse | Outperform |
| 2017-07-10 | 재개 | Leerink Partners | Outperform |
| 2017-06-06 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | 재확인 | RBC Capital Mkts | Sector Perform |
모두보기
Puma Biotechnology Inc 주식(PBYI)의 최신 뉴스
Puma Biotechnology Inc (NASDAQ: PBYI) Share Price, PBYI Stock News, PBYI Share Price & Updates - Kalkine
Puma Biotechnology Advances Alisertib Combo Trial in Small Cell Lung Cancer - TipRanks
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins - Yahoo Finance
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer - biospace.com
Puma Biotechnology initiates phase II lung cancer trial By Investing.com - Investing.com Nigeria
Puma Biotechnology initiates phase II lung cancer trial - Investing.com
Puma Biotechnology Director Wilson Troy Edward Offloads 5,000 Shares at $9.10 on September 14, 2026 - Kalkine Media
PUMA BIOTECHNOLOGY (NASDAQ: PBYI) Director Cesano Alessandra Sells 62,150 Shares at $9.12 Following Option Exercise - Kalkine Media
Puma biotechnology director Cesano sells shares worth $566,994 By Investing.com - Investing.com Canada
Puma Biotechnology director Troy Wilson sells $45,500 in stock By Investing.com - Investing.com Canada
Puma biotechnology director Cesano sells shares worth $566,994 - Investing.com
Puma Biotechnology director Troy Wilson sells $45,500 in stock - Investing.com
Puma Biotechnology (NASDAQ: PBYI) director exercises 50K options, sells 62K shares - stocktitan.net
Puma Biotechnology (PBYI) Trades Essentially Flat at $9.26, Holding Above $8.80 SupportSweep Order Flow - careplusvn.com
Puma Biotechnology at H.C. Wainwright conference: sales, pipeline gains - Investing.com
Puma Biotechnology at H.C. Wainwright conference: sales, pipeline gains By Investing.com - Investing.com Canada
Insider at Puma Biotechnology (NASDAQ: PBYI) files notice to sell shares - Stock Titan
Puma Biotechnology (PBYI) director lines up $45.5K stock sale - Stock Titan
Puma Biotechnology CEO Alan Auerbach presents at H.C. Wainwright Global Investment Conference - Bitget
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference - BioSpace
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound? - Zacks Investment Research
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise (NASDAQ:PBYI) - Seeking Alpha
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why - Eastern Progress
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)September 3, 2026 - biospace.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
InvestingPro’s fair value model spotted Puma Biotech’s 95% rally By Investing.com - Investing.com
Puma Biotechnology (PBYI) Pulls Back 1.93% to $9.14, Pressing Closer to Key SupportMcClellan Summation - vinanet.vn
PBYI | PUMA BIOTECHNOLOGY INC FinancialsRevenue Breakdown - Quiver Quantitative
Puma (PBYI) Latest Quarter: The Available Earnings Metric Delivers a Beat; Investor Response: The Stock Ends Down 4.00% for the Current SessionEarnings Call Q&A - careplusvn.com
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript - AOL.com
Puma (PBYI) Latest Quarter: EPS Lands Above Forecast in the Current Update; Trading Move: Shares Move 4.76% Up in the Latest SessionEPS Growth Report - vinanet.vn
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen - MarketBeat
Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? - Yahoo Finance
Puma Biotechnology, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-08-10 - Seeking Alpha
Puma Biotechnology Reports $56.5M Revenue and Profitability in Q2 - sekbernews.id
Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades - Sahm
Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Puma Biotech earnings beat by $0.16, revenue topped estimates - Investing.com Nigeria
TD Cowen Forecasts Strong Price Appreciation for Puma Biotechnology (NASDAQ:PBYI) Stock - marketbeat.com
Transcript : Puma Biotechnology, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised - Yahoo Finance
Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares - Investing.com
Puma Biotechnology Q2 Earnings Call Highlights - MarketBeat
Puma Biotechnology Reports Second Quarter 2026 Financial Results - biospace.com
Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ... - finance.yahoo.com
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings call transcript: Puma Biotechnology tops Q2 2026 estimates as profit returns - Investing.com
Puma Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Puma Biotech: Q2 Earnings Snapshot - aol.com
Puma Biotechnology Inc (PBYI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Puma Biotechnology Inc 주식 (PBYI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cesano Alessandra | Director |
Sep 14 '26 |
Option Exercise |
2.93 |
50,000 |
146,500 |
118,850 |
| Cesano Alessandra | Director |
Sep 14 '26 |
Sale |
9.12 |
62,150 |
566,994 |
56,700 |
5.32%
자본화:
|
볼륨(24시간):